tiprankstipranks
Benitec Biopharma (BNTC)
NASDAQ:BNTC
US Market
BNTC
Benitec Biopharma
RESEARCH TOOLSreports
Want to see BNTC full AI Analyst Report?

Benitec Biopharma (BNTC) Stock Forecast & Price Target

318 Followers
See the Price Targets and Ratings of:

BNTC Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Benitec
Biopharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BNTC Stock 12 Month Forecast

Average Price Target

$25.00
▲(77.56% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Benitec Biopharma in the last 3 months. The average price target is $25.00 with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 77.56% change from the last price of $14.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","15":"$15","21":"$21","27":"$27","33":"$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,15,21,27,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,13.492307692307692,15.034615384615384,16.576923076923077,18.119230769230768,19.661538461538463,21.203846153846154,22.746153846153845,24.28846153846154,25.83076923076923,27.373076923076923,28.915384615384614,30.45769230769231,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,12.953846153846154,13.957692307692307,14.96153846153846,15.965384615384615,16.96923076923077,17.973076923076924,18.976923076923075,19.98076923076923,20.984615384615385,21.988461538461536,22.99230769230769,23.996153846153845,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,12.415384615384614,12.88076923076923,13.346153846153845,13.811538461538461,14.276923076923076,14.742307692307692,15.207692307692307,15.673076923076923,16.138461538461538,16.603846153846153,17.06923076923077,17.534615384615385,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.775,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$32.00Average Price Target$25.00Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on BNTC
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$18
Buy
27.84%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on Benitec Biopharma (BNTC)
TD Cowen Analyst forecast on BNTC
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/14/26
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
Evercore ISI Analyst forecast on BNTC
Cory Kasimov
Evercore ISI
Evercore ISI
$25
Buy
77.56%
Upside
Initiated
05/12/26
Benitec Biopharma initiated with an Outperform at Evercore ISIBenitec Biopharma initiated with an Outperform at Evercore ISI
H.C. Wainwright Analyst forecast on BNTC
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$32
Buy
127.27%
Upside
Reiterated
03/09/26
Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target
Citizens JMP Analyst forecast on BNTC
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$20→$22
Buy
56.25%
Upside
Reiterated
11/04/25
Benitec Biopharma price target raised to $22 from $20 at Citizens JMPBenitec Biopharma price target raised to $22 from $20 at Citizens JMP
Piper Sandler Analyst forecast on BNTC
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$30
Buy
113.07%
Upside
Reiterated
09/24/25
Piper Sandler Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on BNTC
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$18
Buy
27.84%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on Benitec Biopharma (BNTC)
TD Cowen Analyst forecast on BNTC
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/14/26
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
Evercore ISI Analyst forecast on BNTC
Cory Kasimov
Evercore ISI
Evercore ISI
$25
Buy
77.56%
Upside
Initiated
05/12/26
Benitec Biopharma initiated with an Outperform at Evercore ISIBenitec Biopharma initiated with an Outperform at Evercore ISI
H.C. Wainwright Analyst forecast on BNTC
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$32
Buy
127.27%
Upside
Reiterated
03/09/26
Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target
Citizens JMP Analyst forecast on BNTC
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$20→$22
Buy
56.25%
Upside
Reiterated
11/04/25
Benitec Biopharma price target raised to $22 from $20 at Citizens JMPBenitec Biopharma price target raised to $22 from $20 at Citizens JMP
Piper Sandler Analyst forecast on BNTC
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$30
Buy
113.07%
Upside
Reiterated
09/24/25
Piper Sandler Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Benitec Biopharma

3 Months
Yasmeen RahimiPiper Sandler
Success Rate
7/9 ratings generated profit
78%
Average Return
+10.87%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.87% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
6/9 ratings generated profit
67%
Average Return
+23.09%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +23.09% per trade.
2 Years
Silvan TuerkcanCitizens JMP
Success Rate
17/23 ratings generated profit
74%
Average Return
+108.13%
Copying Silvan Tuerkcan's trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +108.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTC Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
1
3
2
4
Buy
2
1
1
1
1
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
2
4
3
6
In the current month, BNTC has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BNTC average Analyst price target in the past 3 months is 25.00.
Each month's total comprises the sum of three months' worth of ratings.

BNTC Financial Forecast

BNTC Earnings Forecast

Next quarter’s earnings estimate for BNTC is -$0.28 with a range of -$0.35 to -$0.24. The previous quarter’s EPS was -$0.24. BNTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BNTC has Performed in-line its overall industry.
Next quarter’s earnings estimate for BNTC is -$0.28 with a range of -$0.35 to -$0.24. The previous quarter’s EPS was -$0.24. BNTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BNTC has Performed in-line its overall industry.

BNTC Sales Forecast

Next quarter’s sales forecast for BNTC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BNTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BNTC has Performed in-line its overall industry.
Next quarter’s sales forecast for BNTC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BNTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BNTC has Performed in-line its overall industry.

BNTC Stock Forecast FAQ

What is BNTC’s average 12-month price target, according to analysts?
Based on analyst ratings, Benitec Biopharma’s 12-month average price target is 25.00.
    What is BNTC’s upside potential, based on the analysts’ average price target?
    Benitec Biopharma has 77.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BNTC a Buy, Sell or Hold?
          Benitec Biopharma has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Benitec Biopharma’s price target?
            The average price target for Benitec Biopharma is 25.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $32.00 ,the lowest forecast is $18.00. The average price target represents 77.56% Increase from the current price of $14.08.
              What do analysts say about Benitec Biopharma?
              Benitec Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of BNTC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.